Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 55,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) traded down $1.95 during trading hours on Thursday, hitting $39.75. The stock had a trading volume of 625,681 shares, compared to its average volume of 553,900. The stock has a market cap of $2,040.00, a price-to-earnings ratio of 36.14 and a beta of 1.17. Supernus Pharmaceuticals Inc has a 52-week low of $23.10 and a 52-week high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities research analysts expect that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.
SUPN has been the topic of several research analyst reports. Piper Jaffray Companies reissued a “hold” rating and set a $41.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price target on the stock. SunTrust Banks reissued a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Finally, Zacks Investment Research cut Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $50.00.
COPYRIGHT VIOLATION NOTICE: “Supernus Pharmaceuticals Inc (SUPN) VP Sells $2,206,050.00 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/04/supernus-pharmaceuticals-inc-supn-vp-sells-2206050-00-in-stock.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.